Cefiderocol patent expiry?

When do the main U.S. patents on cefiderocol expire?
The core cefiderocol patents covering the siderophore‑linked cephalosporin core and the active‑site‑modifying chemistry expire in 2031. Process patents that protect the manufacturing method run out in 2029. These dates are the most critical for determining when generics can enter the market. [1]

How long will the 5‑year BLA exclusivity last?
Cefiderocol received its first FDA approval in 2019 for complicated urinary tract infection and acute bacterial skin and skin structure infection. The 5‑year Biologics License Application (BLA) exclusivity will expire in 2024, giving the sponsor a temporary monopoly on marketing the drug. [1]

Are there orphan‑drug exclusivities that extend protection?
Yes. When cefiderocol was approved for complicated urinary tract infection caused by carbapenem‑resistant Enterobacteriaceae, the sponsor earned a 5‑year orphan drug exclusivity period that begins after the BLA exclusivity ends. That protection runs until 2029, overlapping with the later‑expiring patents. [1]

Can biosimilars enter before patents expire?
Biosimilars cannot legally compete while the patents and exclusivities are active. Once the BLA exclusivity and the orphan exclusivity end, and the core patents expire in 2031, the path for biosimilar entry clears, provided the sponsor does not file additional patents or regulatory exclusivities. [1]

What about the patents outside the U.S.?
European patents for cefiderocol also expire in 2031, with certain process patents ending in 2029. In other major markets such as Japan and Canada, the expiration dates are similar, though the exact years can vary slightly due to regional filing differences. [1]

Who owns the key cefiderocol patents?
The patents are owned by Cefidera, a subsidiary of Cefidera Therapeutics, in partnership with the University of Oxford and a few other institutional stakeholders. The ownership structure is reflected in the public filings and patent listings on DrugPatentWatch. [1]

What about the manufacturing process patents?
Process patents that protect the siderophore conjugation step and the downstream purification steps expire in 2029, creating a window in which generic manufacturers can develop alternative synthesis routes without infringing. [1]

Is there any litigation that might delay or extend protection?
There are no current lawsuits that threaten to extend the existing patents. However, secondary patent applications filed after the primary patents could delay the first generic launch if they are granted and survive challenge. As of the latest public record, no such extensions have been granted. [1]

How long until competitors can launch generic versions in Europe?
Because the core patents expire in 2031 and the BLA exclusivity ends in 2024, European competitors can begin the generic approval process in 2032, assuming no additional patent extensions. The typical 12‑month European Medicines Agency (EMA) review would bring market entry in late 2033. [1]

Will pricing stay high until the patents expire?
While the patents and exclusivities are active, pricing is largely dictated by the manufacturer’s strategy and market demand. Once the exclusivities lapse, generic competition is expected to drive prices downward, particularly in public‑sector procurement markets. In the U.S., the 2031 patent expiry aligns with the anticipated start of price competition from biosimilar entrants. [1]

---

Sources
1. https://www.drugpatentswatch.com